

Geostar Mineral CORP  
Form 10-Q  
September 18, 2009

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D. C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

For the quarter ended July 31, 2008

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Commission file number 000-53051

Advanced BioMedical Technologies, Inc.  
(Exact name of registrant as specified in its charter)

Nevada  
(State or other jurisdiction of incorporation or organization)

18 Lake Ridge Drive  
Middletown, NY 10940  
(Address of principal executive offices, including zip code.)

(718) 766-7898  
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES  NO

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a small reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "small reporting company" in Rule 12b-2 of the Exchange Act.

Edgar Filing: Geostar Mineral CORP - Form 10-Q

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes  No

As of September 17, 2009, there are 55,614,000 shares of common stock outstanding.

All references in this Report on Form 10-Q to the terms “we”, “our”, “us”, the “Company”, “ABMT” and the “Registrant” refer to Advanced BioMedical Technologies, Inc.

---

ITEM 1. FINANCIAL STATEMENTS

The accompanying condensed unaudited financial statements of Advanced BioMedical Technologies, Inc., formerly known as Geostar Mineral Corporation, a Nevada corporation are condensed and, therefore, do not include all disclosures normally required by accounting principles generally accepted in the United States of America. These statements should be read in conjunction with the Company's most recent annual financial statements for the year ended October 31, 2008 included in our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission ("SEC") on February 13, 2009. In the opinion of management, all adjustments necessary for a fair presentation have been included in the accompanying condensed financial statements and consist of only normal recurring adjustments. The results of operations presented in the accompanying condensed financial statements for the period ended July 31, 2009 are not necessarily indicative of the operating results that may be expected for the full year ending October 31, 2009.

---

ADVANCED BIOMEDICAL TECHNOLOGIES, INC  
AND SUBSIDIARIES  
(A DEVELOPMENT STAGE COMPANY)

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
AS OF JULY 31, 2009  
(UNAUDITED)

---

ADVANCED BIOMEDICAL TECHNOLOGIES, INC AND SUBSIDIARIES  
(A DEVELOPMENT STAGE COMPANY)

CONTENTS

	Pages
<u>Condensed Consolidated Balance Sheets as of July 31, 2009 (unaudited) and October 31, 2008 (audited)</u>	F-1
<u>Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended July 31, 2009 and 2008 (unaudited) and the period from inception September 25, 2002 through July 31, 2009 (unaudited)</u>	F-2
<u>Consolidated Statements of Cash Flows for the nine months ended July 31, 2009 and 2008 (unaudited) and the period from inception September 25, 2002 through July 31, 2009 (unaudited)</u>	F-3
<u>Notes to Condensed Consolidated Financial Statements (unaudited)</u>	F-4 – F-8

---

ADVANCED BIOMEDICAL  
TECHNOLOGIES, INC. ("ABMT")  
AND SUBSIDIARIES  
(A DEVELOPMENT STAGE COMPANY)  
CONDENSED CONSOLIDATED  
BALANCE SHEETS

## ASSETS

	July 31 2009 Unaudited	October 31 2008 Audited
<b>CURRENT ASSETS</b>		
Cash and cash equivalents	\$58,149	\$78,876
Other receivables and prepaid expenses	17,143	8,161
Due from a noncontrolling stockholder of a subsidiary	765	-
<b>Total Current Assets</b>	<b>76,057</b>	<b>87,037</b>
<b>PROPERTY AND EQUIPMENT, NET</b>	<b>77,375</b>	<b>80,743</b>
<b>TOTAL ASSETS</b>	<b>\$153,432</b>	<b>\$167,780</b>
<b>LIABILITIES AND STOCKHOLDERS' DEFICIT</b>		
<b>CURRENT LIABILITIES</b>		
Other payables and accrued expenses	\$21,216	\$26,992
Due to a noncontrolling stockholder of a subsidiary	-	3,123
Due to a stockholder	330,469	85,156
Due to directors	238,230	251,713
Due to a related company	390,203	389,667
Due to a related party	332,877	161,553
<b>Total Current Liabilities</b>	<b>1,312,995</b>	<b>918,204</b>
<b>COMMITMENTS AND CONTINGENCIES</b>	<b>-</b>	<b>-</b>
<b>EQUITY</b>		
<b>ABMT Shareholder's equity</b>		
Common stock, \$0.00001 par value, 100,000,000 shares authorized and 55,614,000 shares issued and outstanding as of July 31, 2009 and 50,510,000 shares issued and outstanding as of October 31, 2008	556	505
Additional paid-in capital	384,462	392,074
Accumulated deficit during development stage	(1,461,348)	(1,060,813)
Accumulated other comprehensive loss	(83,233 )	(82,190 )
<b>Total AMBT Stockholders' Deficit</b>	<b>(1,159,563)</b>	<b>(750,424 )</b>
Noncontrolling interests	-	-
<b>Total Equity</b>	<b>(1,159,563)</b>	<b>(750,424 )</b>
<b>TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT</b>	<b>\$153,432</b>	<b>\$167,780</b>

The accompanying notes are an integral part of these condensed consolidated financial statements

F-1

---

ADVANCED BIOMEDICAL  
TECHNOLOGIES, INC. AND  
SUBSIDIARIES  
(A DEVELOPMENT STAGE COMPANY)  
CONDENSED CONSOLIDATED  
STATEMENTS OF OPERATIONS  
AND COMPREHENSIVE LOSS  
(UNAUDITED)

	Three months ended		Nine months ended		September 25, 2002 (Inception) through July 31,2009
	July 31,		July 31,		
	2009	2008	2009	2008	
<b>OPERATING EXPENSES</b>					
General and administrative expenses	\$97,821	\$45,960	\$327,941	\$92,448	\$1,174,156
Depreciation	7,393	10,400	23,871	34,280	229,294
Research and development (Net of government grant)	(2,984 )	11	394	757	97,428
	102,230	56,371	352,206	127,485	1,500,878
<b>LOSS FROM OPERATIONS</b>	<b>(102,230 )</b>	<b>(56,371 )</b>	<b>(352,206 )</b>	<b>(127,485 )</b>	<b>(1,500,878)</b>
<b>OTHER INCOME (EXPENSES)</b>					